CD276 and non-small cell lung carcinoma: Li et al. [191] utilized bioengineered B7-H3 CAR-T cells co-expressing the chemokine receptor CCR2b, targeting the high expression of the chemokine CCL2 in both primary NSCLC and NSCLC BM.